TCGA-55-A48X-01A-11R-A24H-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 63
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- BILE_ACID_METABOLISM+0.240
- NOTCH_SIGNALING+0.220
- INTERFERON_GAMMA_RESPONSE+0.170
- APICAL_JUNCTION+0.160
- COMPLEMENT+0.150
- IL6_JAK_STAT3_SIGNALING+0.130
- ALLOGRAFT_REJECTION+0.120
- INTERFERON_ALPHA_RESPONSE+0.120
- MYOGENESIS+0.090
- WNT_BETA_CATENIN_SIGNALING+0.080
Top 10 suppressed
- MYC_TARGETS_V2-0.660
- E2F_TARGETS-0.620
- MYC_TARGETS_V1-0.600
- G2M_CHECKPOINT-0.560
- OXIDATIVE_PHOSPHORYLATION-0.560
- MTORC1_SIGNALING-0.490
- UNFOLDED_PROTEIN_RESPONSE-0.450
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.420
- PANCREAS_BETA_CELLS-0.370
- DNA_REPAIR-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-55-7573-01A-11R-2039-07 | — | cohortA1 | 0.901 |
| 2 | TCGA-MP-A4TH-01A-31R-A262-07 | — | cohortA1 | 0.894 |
| 3 | TCGA-NJ-A55A-01A-11R-A262-07 | — | cohortA1 | 0.892 |
| 4 | TCGA-93-A4JP-01A-11R-A24X-07 | — | cohortA1 | 0.878 |
| 5 | TCGA-50-8457-01A-11R-2326-07 | — | cohortA1 | 0.876 |
| 6 | C3N-02451 | — | cohortA1 | 0.874 |
| 7 | MNG904 | — | — | 0.869 |
| 8 | TCGA-55-A57B-01A-12R-A39D-07 | — | cohortA1 | 0.866 |
| 9 | SRR8526730 | — | cohortA1 | 0.865 |
| 10 | TCGA-97-8172-01A-11R-2287-07 | — | cohortA1 | 0.857 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| BILE_ACID_METABOLISM | 0.240 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.220 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.170 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.160 | Inavolisib | — uncovered |
| COMPLEMENT | 0.150 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.130 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.120 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.120 | Inavolisib | — uncovered |
| MYOGENESIS | 0.090 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.080 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.070 | Inavolisib | — uncovered |
| PEROXISOME | 0.070 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.060 | Inavolisib | — uncovered |
| COAGULATION | 0.040 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.040 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.030 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.020 | Temsirolimus | — uncovered |